CXCR4 Antibody (Rabbit mAb) [N1P5]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 - 1:10000 IF1:500 FCM1:200

Application
WB, IHC, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
40 kDa 43 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CXCR4 Antibody (Rabbit mAb) [N1P5] detects endogenous levels of total CXCR4 protein.

Clone
N1P5

Synonym(s)
CD184, C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, FB22, Fusin, HM89, LCR1, NPYRL, Stromal cell-derived factor 1 receptor, LESTR, LAP-3, LPS-associated protein 3, SDF-1 receptor, CXCR4

Background
C‑X‑C chemokine receptor type 4 (CXCR4, also known as CD184) is a seven‑transmembrane G protein–coupled receptor that specifically recognizes the chemokine CXCL12/SDF‑1 and serves as both a key regulator of leukocyte trafficking and a co‑receptor for entry of T‑tropic HIV‑1 strains. CXCR4 displays the canonical GPCR architecture with a bundle of seven α‑helices traversing the membrane, extracellular N‑terminal and loop regions that form the chemokine and viral envelope binding site, and intracellular loops and C‑terminal tail that couple to heterotrimeric G proteins and downstream signaling machinery. Binding of CXCL12 to CXCR4 triggers conformational changes that engage G proteins and activate signaling cascades including PI3K/AKT, ERK/MAPK and small GTPases, leading to cytoskeletal rearrangements, chemotaxis, cell survival and angiogenic responses; CXCL12–CXCR4 signaling is essential for homing and retention of hematopoietic stem cells in bone marrow, B‑cell positioning and trafficking in lymphoid organs, and guidance of newly generated neurons during development and adult neurogenesis. Structural and mutational analyses identify acidic and aromatic residues in the N‑terminal domain (Asp20, Tyr21) and acidic residues in extracellular loop 3 (Glu268) as critical for chemokine binding, while Tyr190 in extracellular loop 2 is required for signal transduction, and the same N‑terminal and extracellular loop regions participate in recognition of HIV‑1 gp120 and in co‑receptor function, placing these segments at the core of both chemokine and viral interactions. CXCR4 also recognizes additional ligands such as vMIP‑II, an antagonistic chemokine encoded by human herpesvirus 8, and can bind ubiquitin and macrophage migration inhibitory factor (MIF), expanding its ligand repertoire and integrating inflammatory and damage-associated signals into CXCR4‑dependent pathways. In the context of HIV pathogenesis, CXCR4 acts with CD4 to permit entry of T‑tropic isolates, and binding of SDF‑1α or vMIP‑II to CXCR4 can inhibit HIV‑1 entry via this co‑receptor, providing a mechanistic basis for chemokine‑mediated antiviral effects and informing structure‑guided design of CXCR4 antagonists such as small molecules and peptides that block gp120 engagement. CXCR4–CXCL12 signaling supports progenitor cell homing and retention, cell arrest and survival, and neovascularization in ischemic and inflammatory settings; pharmacologic blockade of CXCR4 with agents such as plerixafor mobilizes hematopoietic stem cells into peripheral blood for transplantation and has been explored as a strategy to disrupt tumor–stroma interactions and limit metastatic spread to CXCL12‑rich organs including bone marrow, lung and liver. Dysregulated CXCR4 expression occurs in over twenty solid and hematologic malignancies, where high receptor levels correlate with increased migration toward CXCL12 gradients, enhanced angiogenesis and poor prognosis, while germline gain‑of‑function mutations in CXCR4 underlie WHIM syndrome, a primary immunodeficiency characterized by warts, hypogammaglobulinemia, infections and myelokathexis due to impaired leukocyte egress and aberrant B‑cell development.

Background

C‑X‑C chemokine receptor type 4 (CXCR4, also known as CD184) is a seven‑transmembrane G protein–coupled receptor that specifically recognizes the chemokine CXCL12/SDF‑1 and serves as both a key regulator of leukocyte trafficking and a co‑receptor for entry of T‑tropic HIV‑1 strains. CXCR4 displays the canonical GPCR architecture with a bundle of seven α‑helices traversing the membrane, extracellular N‑terminal and loop regions that form the chemokine and viral envelope binding site, and intracellular loops and C‑terminal tail that couple to heterotrimeric G proteins and downstream signaling machinery. Binding of CXCL12 to CXCR4 triggers conformational changes that engage G proteins and activate signaling cascades including PI3K/AKT, ERK/MAPK and small GTPases, leading to cytoskeletal rearrangements, chemotaxis, cell survival and angiogenic responses; CXCL12–CXCR4 signaling is essential for homing and retention of hematopoietic stem cells in bone marrow, B‑cell positioning and trafficking in lymphoid organs, and guidance of newly generated neurons during development and adult neurogenesis. Structural and mutational analyses identify acidic and aromatic residues in the N‑terminal domain (Asp20, Tyr21) and acidic residues in extracellular loop 3 (Glu268) as critical for chemokine binding, while Tyr190 in extracellular loop 2 is required for signal transduction, and the same N‑terminal and extracellular loop regions participate in recognition of HIV‑1 gp120 and in co‑receptor function, placing these segments at the core of both chemokine and viral interactions. CXCR4 also recognizes additional ligands such as vMIP‑II, an antagonistic chemokine encoded by human herpesvirus 8, and can bind ubiquitin and macrophage migration inhibitory factor (MIF), expanding its ligand repertoire and integrating inflammatory and damage-associated signals into CXCR4‑dependent pathways. In the context of HIV pathogenesis, CXCR4 acts with CD4 to permit entry of T‑tropic isolates, and binding of SDF‑1α or vMIP‑II to CXCR4 can inhibit HIV‑1 entry via this co‑receptor, providing a mechanistic basis for chemokine‑mediated antiviral effects and informing structure‑guided design of CXCR4 antagonists such as small molecules and peptides that block gp120 engagement. CXCR4–CXCL12 signaling supports progenitor cell homing and retention, cell arrest and survival, and neovascularization in ischemic and inflammatory settings; pharmacologic blockade of CXCR4 with agents such as plerixafor mobilizes hematopoietic stem cells into peripheral blood for transplantation and has been explored as a strategy to disrupt tumor–stroma interactions and limit metastatic spread to CXCL12‑rich organs including bone marrow, lung and liver. Dysregulated CXCR4 expression occurs in over twenty solid and hematologic malignancies, where high receptor levels correlate with increased migration toward CXCL12 gradients, enhanced angiogenesis and poor prognosis, while germline gain‑of‑function mutations in CXCR4 underlie WHIM syndrome, a primary immunodeficiency characterized by warts, hypogammaglobulinemia, infections and myelokathexis due to impaired leukocyte egress and aberrant B‑cell development.

References
https://pubmed.ncbi.nlm.nih.gov/23382779/ https://pubmed.ncbi.nlm.nih.gov/11551942/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%